Keay Nakae
Stock Analyst at Chardan Capital
(4.36)
# 377
Out of 5,113 analysts
253
Total ratings
42.97%
Success rate
25.46%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.84 | +189.26% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $66.91 | +19.56% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $2 | $0.30 | +560.28% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $29.51 | +18.60% | 1 | Jan 5, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $30 | $16.81 | +78.47% | 1 | Jan 5, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $4.28 | +180.37% | 19 | Dec 18, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $18.04 | +110.64% | 14 | Dec 9, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.52 | +64.47% | 7 | Nov 20, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.16 | +20.19% | 14 | Nov 14, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $70.10 | +42.65% | 6 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.16 | +380.77% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $7 | $10.74 | -34.82% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 | $72.65 | -0.89% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.68 | +138.81% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $5.11 | +584.93% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $354.75 | +12.76% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.28 | +119.30% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $15.44 | -61.14% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.06 | +191.26% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.59 | +1,244.76% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $19.17 | -68.70% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $6.95 | +5,367.63% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.22 | +350.08% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.45 | +124.72% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $35.53 | +146.27% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.59 | +717.61% | 3 | Feb 9, 2021 |
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.84
Upside: +189.26%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $66.91
Upside: +19.56%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $2
Current: $0.30
Upside: +560.28%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $29.51
Upside: +18.60%
Alto Neuroscience
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $16.81
Upside: +78.47%
SAB Biotherapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $4.28
Upside: +180.37%
Dyne Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $18.04
Upside: +110.64%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.52
Upside: +64.47%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.16
Upside: +20.19%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $70.10
Upside: +42.65%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.16
Upside: +380.77%
Nov 13, 2025
Downgrades: Neutral
Price Target: $25 → $7
Current: $10.74
Upside: -34.82%
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $72.65
Upside: -0.89%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.68
Upside: +138.81%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $5.11
Upside: +584.93%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $354.75
Upside: +12.76%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $2.28
Upside: +119.30%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $15.44
Upside: -61.14%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $2.06
Upside: +191.26%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.59
Upside: +1,244.76%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $19.17
Upside: -68.70%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $6.95
Upside: +5,367.63%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $12.22
Upside: +350.08%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.45
Upside: +124.72%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $35.53
Upside: +146.27%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.59
Upside: +717.61%